Patients maintaining NEDA-3 throughout the follow-up period had a median (IQR) CXCL13 concentration of 8.5 (4–28) pg/mL; patients with EDA had 19 (4–56) pg/mL (p = 0.31). Here, CXCL13 is linked to hypohidrotic ectodermal dysplasia.